🇺🇸 FDA

Drug profile · INN

aripiprazole

ABILIFY MYCITE

approved N05AX12
US status
approved
Patents linked
2
News articles
0

Quick answer

aripiprazole (ABILIFY MYCITE) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: intramuscular. Current US regulatory status: approved.

Key facts

INN aripiprazole
Brand ABILIFY MYCITE
Route INTRAMUSCULAR
Formulation TABLET, ORALLY DISINTEGRATING
ATC code N05AX12
Originator Amneal Pharma Europe Ltd

Related patents

Search patents →

  1. US 8865722

    Wet formulations of aripiprazole

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7504504

    Methods of preparing aripiprazole crystalline forms

    Expires Mon Mar 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is aripiprazole?

aripiprazole (ABILIFY MYCITE) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: intramuscular. Current US regulatory status: approved.

What is the brand name for aripiprazole?

ABILIFY MYCITE is a marketed brand name for aripiprazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of aripiprazole?

aripiprazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.